Sector News

Top 10 life sciences trends to watch for in 2018

February 23, 2018
Life sciences

Last year saw life sciences companies take important steps to advance their business processes and drive greater efficiencies in drug development and commercial operations. The groundwork has been laid for the industry to embrace transformation initiatives at a faster pace in 2018.

With that in mind, here are ten trends Veeva predicts will impact life sciences organisations this year:

1. Immunotherapies (i.e. CAR-T cell) will Inspire a new business model

The unique development approach and pricing models introduced with CAR-T will transform the typical pharmaceutical business model. Innovative pricing models such as Novartis’ money-back guarantee on Kymriah mark a true paradigm shift, which will continue to inspire drug manufacturers to rethink their approaches.

2. Augmented reality (AR) will continue to change HCP engagement

AR will soon become a powerful part of the educational process as more companies learn how to leverage the technology. In 2018, life sciences companies will begin experimenting with this new format to create HCP presentations that improve learning with 3-D demonstrations.

3. Risk-based everything (RBX) will take centre-stage

The shift to personalised medicine, along with the evolution of adaptive methodologies, is pushing the boundaries of traditional clinical data collection. Risk-based monitoring (RBM) will be replaced this year by risk-based everything (RBX), a new approach in which each data point can be analysed to help companies make better decisions. Modern data management systems will enable the transition to RBX and make it possible to manage the increasing volumes and diversity of data sources.

4. Regulatory and quality teams will come closer together

As companies expand globally, change control and variation management become more difficult. In 2018, regulatory will begin automating the variation management process and start exchanging information with quality teams to eliminate information gaps. This will make it easier to identify impacted product licenses, determine the required variation filings, and develop global submission strategies.

5. The outsourcing industry will modernise the clinical environment

The top eight CROs have consolidated to just six, but represent more than two-thirds of the market. As such, competition is very high, driving CROs to re-examine their operations and expand their offerings to become turnkey partners to sponsors. In 2018, expect to see CROs focusing on modernising their technical and data environments to build differentiation.

6. Companies will adopt new industry technology standards

In 2017, the industry came together to define technology standards for their shared customers to make it easier for them to get drug information and services. This coming year, companies will begin to put these standards into action by adopting technologies that make customer engagement easier.

7. Artificial intelligence (AI) will continue to make breakthroughs in life sciences

Despite higher volumes and increasing diversity of data sources available, life sciences companies are limited in their ability to use it, due to their reliance on a small group of experts and data scientists. In 2018, companies will significantly scale up their use of artificial intelligence for a wider range of commercial applications.

8. Companies will advance global regulatory processes

Life sciences companies are under continued pressure to globalise, and will focus on transforming global operating capabilities by unifying regulatory information management (RIM) technologies. Moving to a common RIM model with shared global systems will streamline processes with local affiliates and countries to work more effectively in a global regulatory environment.

9. Oncology will continue to propel companies to engage stakeholders differently

Product launches for specialised medicine are top of mind for every life sciences company, with oncology drawing the most attention. While the oncology market is growing exponentially in both size and complexity, life sciences companies are rethinking how they can improve customer engagement, with technology set to play a key role in connecting insight and personalising the customer experience.

10. Companies will prepare for submissions that require content and data

Global health authorities have started to request both content and data to conduct their reviews, in order to obtain a more holistic picture of product safety and efficacy. Upcoming regulations such as Identification of Medicinal Products (IDMP) are driving sponsor organisations to carefully examine their approaches to product-related information. As a result, more organisations will begin the transformation of their processes and systems to incorporate both content and data-related elements.

Jan van den Burg is VP of commercial strategy, Europe at Veeva Systems

Source: Pharma Times

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend